Clinical trialsCompany release

Alto Neuroscience says ALTO-207 depression trial on track, with cash funded through 2030

🇺🇸 Alto Neuroscience, Inc. (ANRO) · Tue 10 Nov 2026

The company's Q3 update puts Phase 2b PACE-1 topline data in the second half of 2027, with two Phase 3 trials planned pending FDA alignment.

Alto Neuroscience reported third-quarter 2026 results on 10 November, saying enrolment in the Phase 2b PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) is on track. Topline data are expected in the second half of 2027.

The company also outlined its planned late-stage programme. Two Phase 3 trials are envisaged: PACE-2, which would test ALTO-207 as an adjunctive treatment, and PACE-3, which would test it as monotherapy. Both depend on alignment with the US Food and Drug Administration, and the summary available does not give details of that process or a timetable.

Phase 1 data on a modified-release formulation of ALTO-207 are expected by early 2027, ahead of the PACE-1 readout.

On finances, Alto reported cash of $319.8 million, which it expects to fund operations through 2030. The company noted that a $100 million registered direct offering, completed in July, contributed to that position.

What it means for your team

  • Regulatory teams tracking TRD should note that the Phase 3 design (adjunctive and monotherapy) is still contingent on FDA alignment, so trial parameters may change.
  • The key dates are early 2027 for Phase 1 modified-release data and the second half of 2027 for PACE-1 topline results.
  • Market-access and competitive-intelligence teams can treat the stated cash runway through 2030 as indicating the company expects to fund its planned development steps without new financing, as the company states.

Company's press release (SEC filing): Alto Neuroscience, Inc. ↗

Article written by VigiEye from the official source (Alto Neuroscience, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →